Washington State has become a key player in the biotechnology sector, home to innovative companies advancing medicine, genomics, and biopharmaceutical manufacturing. The state’s biotech industry benefits from a strong research infrastructure, top-tier universities, and a growing network of Washington biotech companies., home to innovative companies working on groundbreaking advancements in medicine, genomics, and biopharmaceutical manufacturing. The state’s biotech sector benefits from a strong research infrastructure, top-tier universities, and a growing network of Washington biotech companies. From antibody-drug conjugates to next-generation sequencing, these companies are making significant contributions to healthcare and scientific research. This blog highlights 10 companies at the forefront of biotech companies in Washington State, detailing their research focus, impact, and contributions to the industry.

‍

‍

Seagen Inc.: Advancing Antibody-Drug Conjugates

Seagen Inc., headquartered in Bothell, Washington, is a leader in antibody-drug conjugate (ADC) technology. ADCs are a class of targeted cancer therapies that deliver cytotoxic drugs directly to tumor cells while sparing healthy tissues. Seagen has developed several FDA-approved ADC therapies, including Adcetris (approved in 2011 for Hodgkin lymphoma) and Padcev (approved in 2019 for urothelial cancer), significantly improving treatment outcomes for these patients., which have significantly improved treatment outcomes for lymphoma and urothelial cancer patients. The company continues to expand its oncology pipeline, leveraging advanced protein engineering and novel payloads to improve efficacy and safety profiles of its drugs. Seagen is among the most influential Washington state pharmaceutical companies driving innovation in cancer treatment.

‍

Adaptive Biotechnologies: Harnessing the Power of Immune-Driven Medicine

Seattle-based Adaptive Biotechnologies specializes in immune system-based diagnostics and therapeutics. The company’s immune sequencing technology enables the detection of T-cell and B-cell receptors, allowing for early disease identification and personalized treatment approaches. Adaptive’s collaboration with Microsoft in machine learning has led to advances in immune-driven medicine, particularly in using AI to map immune responses. Their T-Detect platform applies machine learning to identify immune signatures of diseases, improving early detection., such as the clonoSEQ test for detecting minimal residual disease in blood cancers and the T-Detect platform for early disease detection. Their work in immune repertoire sequencing is shaping the future of diagnostics and treatment in autoimmune diseases and oncology, making them a vital part of the biotech companies Washington landscape.

‍

AGC Biologics: Advancing Biopharmaceutical Manufacturing

AGC Biologics, a contract development and manufacturing organization (CDMO) with facilities in Bothell, Washington, specializes in cell and gene therapy production. The company provides end-to-end services for biologics manufacturing, from process development to commercial production. AGC Biologics has been instrumental in supporting biotech companies in Washington by ensuring scalable and compliant production of complex biologic drugs, including monoclonal antibodies and recombinant proteins. Their expertise in GMP manufacturing and global network make them a trusted partner in bringing biologics to market.

‍

Phase Genomics: Leading Innovation in Genome Sequencing

Located in Seattle, Phase Genomics develops advanced genome assembly and structural variant detection tools. Their proprietary Hi-C sequencing technology enables researchers to map chromosome interactions, analyze microbial communities, and identify structural variants linked to genetic diseases. Phase Genomics’ technology is widely used in agricultural genomics, microbiome research, and precision medicine, providing new insights into genomic architecture and disease pathways. Their contributions make them a standout among Washington biotech companies.

‍

Institute for Systems Biology: Pioneering Systems Medicine

The Institute for Systems Biology (ISB), a non-profit research institution in Seattle, integrates multi-omics data, computational biology, and artificial intelligence to study complex biological systems. Founded by Dr. Leroy Hood, ISB has contributed to major advancements in personalized medicine, early disease detection, and predictive healthcare analytics. The institute’s research spans cancer, neurodegenerative diseases, and aging, fostering interdisciplinary collaborations between scientists, engineers, and healthcare providers to improve disease prevention and treatment strategies. ISB plays a critical role in the broader biotech companies in Washington State ecosystem.

‍

‍

Bristol Myers Squibb (BMS) – Bothell Site: Driving Immuno-Oncology Research

Bristol Myers Squibb (BMS) operates a major research facility in Bothell, Washington, dedicated to immuno-oncology and cell therapy. The site plays a crucial role in developing next-generation treatments for cancer and autoimmune diseases, focusing on CAR-T cell therapy and immune checkpoint inhibitors. BMS’s commitment to advancing cell therapy has led to FDA approvals for groundbreaking treatments such as Breyanzi and Abecma, which offer new hope for patients with hematologic malignancies. Their Bothell site solidifies their position among Washington state pharmaceutical companies leading medical advancements.

‍

TwinStrand Biosciences: Improving DNA Sequencing Accuracy

Seattle-based TwinStrand Biosciences has developed Duplex Sequencing technology, a high-fidelity next-generation sequencing method that dramatically reduces errors in DNA analysis. This technology is crucial for applications requiring ultra-accurate mutation detection, such as early cancer detection, forensic genomics, and genetic disease research. By providing unparalleled sensitivity in DNA sequencing, TwinStrand is enabling more precise diagnostics and accelerating advancements in targeted therapy, reinforcing their place in the biotech companies Washington sector.

‍

Parse Biosciences: Advancing Single-Cell RNA Sequencing

Parse Biosciences, based in Seattle, offers scalable single-cell RNA sequencing solutions that enhance research in cancer, neuroscience, and immunology. Their approach allows researchers to profile thousands of cells simultaneously without the need for complex microfluidic systems, making single-cell analysis more accessible and cost-effective. Parse’s technology is used by research institutions such as Stanford University and pharmaceutical companies for single-cell RNA sequencing, offering insights into cellular heterogeneity in diseases like cancer and neurodegenerative disorders., leading to better insights into cellular heterogeneity and disease mechanisms, securing their role as a key player in Washington biotech companies.

‍

Silverback Therapeutics: Engineering Targeted Immunotherapies

Silverback Therapeutics, headquartered in Seattle, is developing a pipeline of immune-modulating therapies, including SBT6050, a HER2-targeted immune activator currently in clinical trials for treating HER2-expressing solid tumors. designed to activate immune responses against tumors while minimizing systemic toxicity. Their ImmunoTAC platform delivers immune-stimulating agents selectively to tumor sites, improving therapeutic efficacy. The company’s pipeline includes treatments for solid tumors and autoimmune conditions, representing a promising approach in targeted immunotherapy, keeping them at the forefront of biotech companies in Washington.

‍

Cyrus Biotechnology: AI-Powered Protein Design for Drug Discovery

Seattle-based Cyrus Biotechnology leverages artificial intelligence and computational protein modeling to optimize biologics and enzyme therapies. Their cloud-based platform, developed in collaboration with the University of Washington’s Institute for Protein Design, allows researchers to engineer proteins for improved stability, binding affinity, and therapeutic properties. Cyrus’ technology is accelerating drug discovery in infectious diseases, metabolic disorders, and oncology, demonstrating their importance in biotech companies in Washington State.

‍

Conclusion

Washington State’s biotech industry continues to grow, with companies leading advancements in antibody-drug conjugates, immune-driven medicine, and genome sequencing. These organizations are making critical contributions to healthcare, diagnostics, and drug discovery, driving progress in treating cancer, genetic diseases, and autoimmune disorders. With strong research institutions and a collaborative ecosystem, Washington state pharmaceutical companies remain at the forefront of life sciences innovation.

‍

Join the Scientific Revolution at Scispot

Biotech companies face increasing challenges in managing data, optimizing research workflows, and ensuring regulatory compliance. Scispot provides a comprehensive TechBio platform that enables biotech companies in Washington DC and beyond to centralize research data, integrate laboratory instruments, and enhance collaboration across teams. With Scispot’s no-code automation tools, biotech teams can standardize data collection, track experiments more efficiently, and maintain compliance with industry regulations. By using Scispot, Washington DC biotech organizations can reduce operational bottlenecks, accelerate discoveries, and scale their research capabilities effectively. Whether you're a startup or an established biotech firm, Scispot equips you with the digital infrastructure needed to stay competitive in an evolving industry.

‍